WALTHAM, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), announced today that it will be participating in the 3rd annual Disruptive Growth & Healthcare Conference in New York City on May 8-9, 2018 sponsored by RHK Capital and ReedSmith.

WALTHAM, Mass. , May 03, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported that preliminary results from a study of Quell ® wearable pain relief in chronic low back pain will be presented at the 9th World Congress of the World Institute of Pain in Dublin, Ireland May 9-12,

WALTHAM, Mass. , June 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported that it had achieved the first development milestone under its strategic collaboration with GSK Consumer Healthcare . A milestone payment of $3.8 Million was made by GSK.

84 percent of Americans living with chronic pain believe there is a stigma around opioid use; 90 percent are actively seeking alternative treatments WALTHAM, Mass. , June 21, 2018 (GLOBE NEWSWIRE) -- The opioid crisis continues to make headlines, but in the midst of this chaos, members of the

WALTHAM, Mass. , June 26, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported publication of three new clinical studies on DPNCheck ® , a point-of-care device that provides accurate and cost-effective screening, diagnosis, and monitoring of diabetic peripheral neuropathy (DPN).

“Moving Beyond Opioids: How Technological Innovations Can Impact Chronic Pain” earns top award in healthcare publicity campaign category WALTHAM, Mass. , June 28, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) in conjunction with its public relations firm, InkHouse, received two

WALTHAM, Mass. , July 05, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,004,445. The patent covers novel technology that enhances DPNCheck ® device performance by detecting and rejecting erroneous

WALTHAM, Mass. , July 12, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc.(NASDAQ:NURO) announced today that it plans to issue its 2018 second quarter financial results before the opening of the market on Thursday, July 19, 2018. The Company will host a conference call at 8:00 a.m., Eastern

Initial $3.8M Milestone Achieved under GSK Strategic Collaboration WALTHAM, Mass. , July 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported financial and business highlights for the quarter ended June 30, 2018 . The Company develops and markets novel therapies, based on

WALTHAM, Mass. , Aug. 21, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported that it had achieved the second development milestone under its strategic collaboration with GSK Consumer Healthcare . A milestone payment of $3.8 Million was made by GSK.